Checking safer reuse of oxaliplatin in stomach or bowel cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether reusing the chemotherapy drug oxaliplatin is safe for people with gastrointestinal (stomach or bowel) tumors who need oxaliplatin. You may be able to take the drug again under close monitoring to see how well it works and how safe it is, including if you previously had an allergic reaction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You plan to receive oxaliplatin as part of your cancer treatment
- You are between 18 and 75 years old
- Your day-to-day ability is limited but you can still function (ECOG 0 to 2)
- You and your care team expect you will live more than 3 months
- You are willing and able to take part in study surveys
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This Phase 2 study compares giving oxaliplatin by IV for 2 hours versus 6 hours, along with the standard FOLFOX6 chemotherapy. It aims to see if the shorter infusion works as well and is manageable for people with gastrointestinal cancers.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.